Fixed dosage of low‐molecular‐weight heparins causes large individual variation in coagulability, only partly correlated to body weight
暂无分享,去创建一个
H C Hemker | R. al Dieri | S. Béguin | S Béguin | R Al Dieri | S Alban | S. Alban | R. A. Dieri | H. Hemker
[1] S. Béguin,et al. Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time , 2004, Journal of thrombosis and haemostasis : JTH.
[2] M. Kovacs,et al. Body weight does not predict for anti-Xa levels after fixed dose prophylaxis with enoxaparin after orthopedic surgery. , 1998, Thrombosis research.
[3] V. Kakkar,et al. The Routine Determination of the Endogenous Thrombin Potential, First Results in Different Forms of Hyper- and Hypocoagulability , 1997, Thrombosis and Haemostasis.
[4] H. Hemker,et al. The inhibition of blood coagulation by heparins of different molecular weight is caused by a common functional motif—the C‐domain , 2003, Journal of thrombosis and haemostasis : JTH.
[5] Georgios Nakos,et al. Monitoring , 1976, Encyclopedia of the UN Sustainable Development Goals.
[6] P. de Moerloose,et al. Is laboratory monitoring of low‐molecular‐weight heparin therapy necessary? No , 2004, Journal of thrombosis and haemostasis : JTH.
[7] I. Gouin-Thibault,et al. Safety Profile of Different Low-Molecular Weight Heparins Used at Therapeutic Dose , 2005, Drug safety.
[8] D. Anderson,et al. Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[9] J. Ennker,et al. INR Self-Management Permits Lower Anticoagulation Levels After Mechanical Heart Valve Replacement , 2003, Circulation.
[10] M. Wolzt,et al. The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma. , 2004, Thrombosis research.
[11] M. Samama,et al. Correlation between anti-Xa and occurrence of thrombosis and haemorrhage in post-surgical patients treated with either Logiparin (LMWH) or unfractionated heparin. Post-surgery Logiparin Study Group. , 1992, Thrombosis research.
[12] E. Ohman,et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. , 1998, Chest.
[13] H. Hemker,et al. Phenotyping the Clotting System , 2002, Thrombosis and Haemostasis.
[14] R. al Dieri,et al. Laboratory assessment of antithrombotic therapy: what tests and if so why? , 1997, Haemostasis.
[15] By,et al. A THROMBIN GENERATION TEST THE APPLICATION IN HAEMOPHILIA AND THROMBOCYTOPENIA , 2022 .
[16] H. Hemker,et al. Mode of action of enoxaparin in plasma. , 1990, Acta chirurgica Scandinavica. Supplementum.
[17] A. Fung,et al. A randomized trial of patient self-managed versus physician-managed oral anticoagulation. , 2004, The Canadian journal of cardiology.
[18] D. Fitzmaurice,et al. Patient self‐management of oral anticoagulation and external quality assessment procedures , 2003, British journal of haematology.
[19] G. L. Reijnierse,et al. Monitoring of unfractionated heparin with the activated partial thromboplastin time: determination of therapeutic ranges. , 2002, Thrombosis research.
[20] T. Baglin,et al. Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition , 2004, Journal of thrombosis and haemostasis : JTH.
[21] F. Depasse,et al. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma , 2004, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[22] J. Harenberg. Is laboratory monitoring of low‐molecular‐weight heparin therapy necessary? Yes , 2004, Journal of thrombosis and haemostasis : JTH.
[23] H. Hemker,et al. The Mode of Action of Heparin in Plasma , 1988, Thrombosis and Haemostasis.
[24] Stig L Boström,et al. Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects , 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[25] R. White,et al. Low‐Molecular‐Weight Heparins: Are they all the Same? , 2003, British journal of haematology.
[26] E. Ohman,et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. , 2001, Chest.
[27] P. Ockelford,et al. Audit of community‐based anticoagulant monitoring in patients with thromboembolic disease: is frequent testing necessary? , 2004, Internal medicine journal.
[28] H. Hemker,et al. Pharmacokinetic and Pharmacodynamic Characterization of a Medium-Molecular-Weight Heparin in Comparison with UFH and LMWH , 2002, Seminars in thrombosis and hemostasis.
[29] T. Barrowcliffe. Monitoring haemophilia severity and treatment: new or old laboratory tests? , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.
[30] S. Alban,et al. Plasma Levels of Total and Free Tissue Factor Pathway Inhibitor (TFPI) as Individual Pharmacological Parameters of Various Heparins , 2001, Thrombosis and Haemostasis.
[31] M. Alhenc-Gelas,et al. Adjusted Versus Fixed Doses of the Low-Molecular-Weight Heparin Fragmin in the Treatment of Deep Vein Thrombosis , 1994, Thrombosis and Haemostasis.
[32] J. Hirsh,et al. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.
[33] T. Lindahl,et al. A Critical Evaluation of the Prothrombin Time for Monitoring Oral Anticoagulant Therapy , 2003, Pathophysiology of Haemostasis and Thrombosis.
[34] T. Morris,et al. Pharmacokinetics of UH and LMWH are similar with respect to antithrombin activity. , 2005, Thrombosis research.
[35] J. Sixma,et al. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. , 1991, Blood.
[36] M. Petitou,et al. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. , 1983, Biochemical and biophysical research communications.
[37] H. Hemker,et al. The Mode of Action of Low Molecular Weight Heparin Preparation (PK10169) and Two of its Major Components on Thrombin Generation in Plasma , 1989, Thrombosis and Haemostasis.
[38] Flora Peyvandi,et al. The Thrombogram in Rare Inherited Coagulation Disorders: Its Relation to Clinical Bleeding , 2002, Thrombosis and Haemostasis.
[39] M. Laposata,et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. , 1998, Archives of pathology & laboratory medicine.
[40] L. Norgren,et al. Enoxaparin effect depends on body‐weight and current doses may be inadequate in obese patients , 2003, The British journal of surgery.
[41] J. Renberg. Is laboratory monitoring of low-molecular-weight heparin therapy necessary ? , 2004 .
[42] J. Herbert,et al. New synthetic heparin mimetics able to inhibit thrombin and factor Xa. , 1999, Bioorganic & medicinal chemistry letters.
[43] E. Nutescu,et al. Dosing and Monitoring of Low‐Molecular‐Weight Heparins in Special Populations , 2001, Pharmacotherapy.
[44] S. Béguin,et al. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[45] H C Hemker,et al. Thrombin Generation in Plasma: Its Assessment Via the Endogenous Thrombin Potential , 1995, Thrombosis and Haemostasis.
[46] M. Haugh,et al. Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage. , 1993, Haemostasis.